Our data show that in daily clinical practice, comorbidities and geographical region are significantly associated with receiving adjuvant BRAF/MEK-inhibition therapy or adjuvant anti-PD-1 systemic treatment in patients with resectable stage III melanoma. This evidence concerns the gene BRAF and melanoma.